Publications of Paul Lockman, PhD

A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.
Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR.
Cancer Prev Res (Phila). 2015;8(1):68-76.

PMC4311570.

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR.
BMC Cancer. 2015;15(1):685

PMC4604629.

Molecular determinants of blood-brain barrier permeation.
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR.
Ther Deliv. 2015;6(8):961-971.

PMC4675962.

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD.
Neuro Oncol. 2015;17(2):289-295.

PMC4288517.

Unsanctifying the sanctuary: challenges and opportunities with brain metastases.
Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman PR, McGregor J, Muldoon L, Nesbit G, Peereboom D, Smith Q, Walker S, Neuwelt E.
Neuro Oncol. 2015;17(5):639-651.

PMC4482864.

Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in danio rerio.
Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman PR, Bai S.
Pharm Res. 2015;32(6):2003-2014.

PMC4520542.

Complex issues affecting student pharmacist debt.
Cain J, Campbell T, Congdon HB, Hancock K, Kaun M, Lockman PR, Evans RL.
Am J Pharm Educ. 2014;78(7):131

PMC4174373.

Pharmacy student debt and return on investment of a pharmacy education.
Cain J, Campbell T, Congdon HB, Hancock K, Kaun M, Lockman PR, Evans RL.
Am J Pharm Educ. 2014;78(1):5

PMC3930253.

Novel treatment strategies for brain tumors and metastases.
El-Habashy SE, Nazief AM, Adkins CE, Wen MM, El-Kamel AH, Hamdan AM, Hanafy AS, Terrell TO, Mohammad AS, Lockman PR, Nounou MI.
Pharm Pat Anal. 2014;3(3):279-296.


Crossing the barrier - the role of the blood-brain barrier in treating mental illness.
Adkins CE, Barber KR, Lockman PR.
Biochemist. 2013;35(3):06


P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, Bohn KA, Yasemin C, Grothe TR, Lockman JA, Lockman PR.
Front Pharmacol. 2013;4:136

PMC3816283.

Metastasis of breast tumor cells to brain is suppressed by phenethyl isothiocyanate in a novel metastasis model.
Gupta P, Adkins CE, Lockman PR, Srivastava SK.
PLoS One. 2013;8(6):e67278

PMC3695065.

Paclitaxel-Hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR.
Mol Cancer Ther. 2013;12(11):2389-2399.


Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier.
Mittapalli RK, Manda VK, Bohn KA, Adkins CE, Lockman PR.
J Neurosci Methods. 2013;219(1):188-195.

PMC4319652.

Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA.
Neuroimage. 2012;61(1):228-239.

PMC4455552.

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman JA, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, Smith QR.
Pharm Res. 2012;29(3):770-781.

PMC3489161.

N-Aryl-substituted 3-(beta-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy.
Scott LE, Telpoukhovskaia M, Rodriguez-Rodriguez C, Merkel M, Bowen ML, Page BDG, Green DE, Storr T, Thomas F, Allen DD, Lockman PR, Patrick BO, Adam MJ, Orvig C.
Chemical Science. 2011;2(4):642-648.


Improving educational outcomes of Hispanic students in a professional degree program.
Fike DS, McCall KL, Estes FG, Ndefo UA, Rahel CL, Smith QR, Lockman PR.
Equity & Excellence in Education. 2010;43(4):527-538.


3-D-QSAR and docking studies on the neuronal choline transporter.
Geldenhuys WJ, Allen DD, Lockman PR.
Bioorg Med Chem Lett. 2010;20(16):4870-4877.


Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.
Geldenhuys WJ, Manda VK, Mittapalli RK, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD, Lockman PR.
Bioorg Med Chem Lett. 2010;20(3):870-877.

PMC2818856.

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR.
Clin Cancer Res. 2010;16(23):5664-5678.

PMC2999649.

Nicotine and cotinine increases the brain penetration of saquinavir in rat.
Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR.
J Neurochem. 2010;115(6):1495-1507.


Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity.
Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR.
J Neurochem. 2010;115(2):515-525.


Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules.
Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR.
Ther Deliv. 2010;1(6):775-784.


Varying efficacy of superdisintegrants in orally disintegrating tablets among different manufacturers.
Mittapalli RK, Qhattal HS, Lockman PR, Yamsani MR.
Pharmazie. 2010;65(11):805-810.


Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.
Zheng G, Zhang Z, Lockman PR, Geldenhuys WJ, Allen DD, Dwoskin LP, Crooks PA.
Bioorg Med Chem Lett. 2010;20(11):3208-3210.

PMC3725989.

Achieving equivalent academic performance between campuses using a distributed education model.
Fike DS, McCall KL, Raehl CL, Smith QR, Lockman PR.
Am J Pharm Educ. 2009;73(5):88

PMC2739071.

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS.
Clin Cancer Res. 2009;15(19):6148-6157.


In vivo interactions of magnetic nanoparticles with the blood-brain barrier.
Stepp P, Thomas F, Lockman PR, Chen H, Rosengart AJ.
Journal of Magnetism and Magnetic Materials. 2009;321(10):1591-1593.


Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.
Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR.
Pharm Res. 2009;26(11):2486-2494.

PMC2896053.

Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET.
Deuther-Conrad W, Patt JT, Lockman PR, Allen DD, Patt M, Schildan A, Ganapathy V, Steinbach J, Sabri O, Brust P.
Eur Neuropsychopharmacol. 2008;18(3):222-229.


N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT.
J Pharmacol Exp Ther. 2008;326(2):563-576.

PMC3089982.

Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier.
Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD.
J Pharmacol Exp Ther. 2008;324(1):244-250.


Using WebCt to implement a basic science competency education course.
Lockman PR, Gaasch JA, Borges K, Ehlo A, Smith QR.
Am J Pharm Educ. 2008;72(2):39

PMC2384214.

Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS, Rao US.
Oncol Rep. 2008;19(3):587-594.


bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter.
Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA.
Bioorg Med Chem Lett. 2008;18(20):5622-5625.

PMC3437650.

Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman PR, Papke RL, Bardo MT, Crooks PA.
Biochem Pharmacol. 2007;74(8):1271-1282.

PMC2104778.

Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures.
Gaasch JA, Geldenhuys WJ, Lockman PR, Allen DD, Van der Schyf CJ.
Neurochem Res. 2007;32(10):1686-1693.


Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells.
Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ.
Neurochem Res. 2007;32(7):1196-1208.


Combating Alzheimer's disease with multifunctional molecules designed for metal passivation.
Schugar H, Green DE, Bowen ML, Scott LE, Storr T, Bohmerle K, Thomas F, Allen DD, Lockman PR, Merkel M, Thompson KH, Orvig C.
Angew Chem Int Ed Engl. 2007;46(10):1716-1718.


The blood-brain barrier and brain drug delivery.
Koziara JM, Lockman PR, Allen DD, Mumper RJ.
J Nanosci Nanotechnol. 2006;6(9-10):2712-2735.


Nicotine exposure does not alter plasma to brain choline transfer.
Lockman PR, Gaasch J, McAfee G, Abbruscato TJ, Van der Schyf CJ, Allen DD.
Neurochem Res. 2006;31(4):503-508.


Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, Lindau M, Lockman PR, Manninger SP, Qiang Y, Spence AM, Stupp SI, Zhang M, Neuwelt EA.
AJNR Am J Neuroradiol. 2006;27(3):715-721.


Brain metastases of breast cancer.
Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, Weil RJ, Steeg PS.
Breast Dis. 2006;26:139-147.


Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ.
Eur J Pharm Biopharm. 2005;59(2):263-272.


3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter.
Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD.
Bioorg Med Chem. 2005;13(13):4253-4261.


Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the blood-brain barrier.
Geldenhuys WJ, Lockman PR, Philip AE, McAfee JH, Miller BL, McCurdy CR, Allen DD.
J Drug Target. 2005;13(4):259-266.


Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine.
Lockman PR, Van der Schyf CJ, Abbruscato TJ, Allen DD.
J Neurochem. 2005;94(1):37-44.


Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure.
Lockman PR, McAfee G, Geldenhuys WJ, Van der Schyf CJ, Abbruscato TJ, Allen DD.
J Pharmacol Exp Ther. 2005;314(2):636-642.


Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter.
Geldenhuys WJ, Lockman PR, McAfee JH, Fitzpatrick KT, Van der Schyf CJ, Allen DD.
Bioorg Med Chem Lett. 2004;14(12):3085-3092.


Paclitaxel nanoparticles for the potential treatment of brain tumors.
Koziara JM, Lockman PR, Allen DD, Mumper RJ.
J Control Release. 2004;99(2):259-269.


Nanoparticle surface charges alter blood-brain barrier integrity and permeability.
Lockman PR, Koziara JM, Mumper RJ, Allen DD.
J Drug Target. 2004;12(9-10):635-641.


Cation transport specificity at the blood-brain barrier.
Lockman PR, McAfee JH, Geldenhuys WJ, Allen DD.
Neurochem Res. 2004;29(12):2245-2250.


Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter.
Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA.
J Pharmacol Exp Ther. 2003;304(3):1268-1274.


The blood-brain barrier choline transporter as a brain drug delivery vector.
Allen DD, Lockman PR.
Life Sci. 2003;73(13):1609-1615.


In situ blood-brain barrier transport of nanoparticles.
Koziara JM, Lockman PR, Allen DD, Mumper RJ.
Pharm Res. 2003;20(11):1772-1778.


In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles.
Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD.
Pharm Res. 2003;20(5):705-713.


Brain uptake of thiamine-coated nanoparticles.
Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD.
J Control Release. 2003;93(3):271-282.


Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method.
Lockman PR, Mumper RJ, Allen DD.
J Neurochem. 2003;86(3):627-634.


Novel choline transport characteristics in Caco-2 cells.
Crowe AP, Lockman PR, Abbruscato TJ, Allen DD.
Drug Dev Ind Pharm. 2002;28(7):773-781.


The transport of choline.
Lockman PR, Allen DD.
Drug Dev Ind Pharm. 2002;28(7):749-771.


Nanoparticle technology for drug delivery across the blood-brain barrier.
Lockman PR, Mumper RJ, Khan MA, Allen DD.
Drug Dev Ind Pharm. 2002;28(1):1-13.


Inhibition of the rat blood-brain barrier choline transporter by manganese chloride.
Lockman PR, Roder KE, Allen DD.
J Neurochem. 2001;79(3):588-594.


Trends in ipecac use: a survey of poison center staff.
Marchbanks B, Lockman PR, Shum S, Beard D.
Vet Hum Toxicol. 1999;41(1):47-48.